Kyowa Kirin Korea Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.kyowakirin.com/kr
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Recruiting
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06206135
- Locations
- 🇰🇷
Jesus Hospital, Jeonju, Korea, Republic of
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
Recruiting
- Conditions
- FGF23-related Hypophosphataemic Rickets and Osteomalacia
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06202027
- Locations
- 🇰🇷
Choi Hyeokjun, Seoul, Korea, Republic of
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients
Recruiting
- Conditions
- Hyperphosphatemia
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06186934
- Locations
- 🇰🇷
Jesus Hospital, Jeonju, Korea, Republic of
An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
Completed
- Conditions
- Breast Cancer FemaleBreast Neoplasm Female
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 1300
- Registration Number
- NCT03433560
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Kyoungsang, Korea, Republic of
🇰🇷Bucheon Soonchunhyang University Hospital, Bucheon, Kyounggi, Korea, Republic of
🇰🇷Wonju Severance Christian Hospital, Wonju, Gangwon, Korea, Republic of
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
Phase 3
Completed
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT02982005
- Locations
- 🇰🇷
Korea, Republic of, Seoul, Korea, Republic of
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT02094417
- Locations
- 🇰🇷
Korea, Republic of, Seoul, Korea, Republic of
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Phase 1
Terminated
- Conditions
- Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), MesotheliomaPhase 2 Portion : Small Cell Lung Cancer(SCLC)
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT01898156
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Korea, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath